Published in Clin Exp Metastasis on January 01, 2004
Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer (2009) 1.23
Tumor metastasis to bone. Arthritis Res Ther (2007) 0.98
Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases. BMC Cancer (2007) 0.90
Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis. Clin Exp Metastasis (2008) 0.87
HE3235 inhibits growth of castration-resistant prostate cancer. Neoplasia (2009) 0.87
Bone metastasis: the importance of the neighbourhood. Nat Rev Cancer (2016) 0.86
Serially heterotransplanted human prostate tumours as an experimental model. J Cell Mol Med (2009) 0.80
Down-regulation of osteoprotegerin expression as a novel biomarker for colorectal carcinoma. Oncotarget (2016) 0.78
Expression of osteoprotegerin from a replicating adenovirus inhibits the progression of prostate cancer bone metastases in a murine model. Lab Invest (2013) 0.75
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev (1998) 7.81
RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol (2001) 3.27
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun (1998) 2.66
Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem (1986) 2.50
Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest (2001) 2.49
Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res (2003) 2.14
Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology (1999) 2.11
Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res (1996) 1.98
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood (2001) 1.83
Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate (2002) 1.78
RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am J Clin Pathol (2002) 1.72
Osteoprotegerin and rank ligand expression in prostate cancer. Urology (2001) 1.50
Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res (2001) 1.44
Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol (1987) 1.34
Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer (1983) 1.23
Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol (1991) 1.22
The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change. J Bone Miner Res (1994) 1.21
Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer (2001) 1.18
Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol (1985) 1.16
Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res (2002) 1.16
Mechanisms of the development of osteoblastic metastases. Cancer (1997) 1.12
RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol (2002) 1.10
Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Res (2003) 1.04
Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration. Int J Cancer (1996) 1.01
Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J Surg Res (2001) 0.99
Molecular basis of the spectrum of skeletal complications of neoplasia. Cancer (2000) 0.93
The effects of orchidectomy on skeletal metabolism in metastatic prostate cancer. Scand J Urol Nephrol (1993) 0.83
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res (1997) 665.31
The sequence of the human genome. Science (2001) 101.55
Comparative genomics of the eukaryotes. Science (2000) 26.62
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 17.76
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med (2001) 12.38
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32
The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. EMBO J (2001) 7.97
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev (1998) 7.81
The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ (2007) 7.74
Engineering the provitamin A (beta-carotene) biosynthetic pathway into (carotenoid-free) rice endosperm. Science (2000) 7.53
TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev (1999) 6.93
Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia (2006) 6.31
A potential vulnerability locus for schizophrenia on chromosome 6p24-22: evidence for genetic heterogeneity. Nat Genet (1995) 5.87
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet (2001) 5.80
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A (1999) 5.78
The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet (1997) 5.55
Sites of specific B cell activation in primary and secondary responses to T cell-dependent and T cell-independent antigens. Eur J Immunol (1991) 5.38
The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem (1995) 5.36
Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med (2000) 5.34
Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res (2001) 5.11
A kinase-cyclin pair in the RNA polymerase II holoenzyme. Nature (1995) 4.93
Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology (2001) 4.84
HCFA's racial and ethnic data: current accuracy and recent improvements. Health Care Financ Rev (2000) 4.67
Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev (2001) 4.47
Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A (1998) 4.40
CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology (2007) 4.24
Sequence specificity in the dimerization of transmembrane alpha-helices. Biochemistry (1992) 4.19
An essential role in liver development for transcription factor XBP-1. Genes Dev (2000) 4.17
Comparative analysis of 1196 orthologous mouse and human full-length mRNA and protein sequences. Genome Res (1996) 4.11
The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature (2000) 4.00
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A (2000) 3.95
Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci (2001) 3.85
Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther (2003) 3.85
Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem (1998) 3.77
Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem (1994) 3.73
The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia (2008) 3.69
Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene (2009) 3.64
Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int (2006) 3.64
A local alignment tool for very long DNA sequences. Comput Appl Biosci (1995) 3.58
Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease. Nat Genet (2001) 3.48
The beta2-adrenergic receptor/betaarrestin complex recruits the clathrin adaptor AP-2 during endocytosis. Proc Natl Acad Sci U S A (1999) 3.43
The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ (2009) 3.43
Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet (1999) 3.39
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res (2000) 3.38
Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway. Genes Dev (2000) 3.38
Mutation in the silencing gene SIR4 can delay aging in S. cerevisiae. Cell (1995) 3.37
Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med (1995) 3.32
CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity (2000) 3.28
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol (2000) 3.24
Influenza virus hemagglutinin and neuraminidase cytoplasmic tails control particle shape. EMBO J (1997) 3.23
Cell-cell interaction in prostate gene regulation and cytodifferentiation. Proc Natl Acad Sci U S A (1997) 3.22
BCL-6 protein is expressed in germinal-center B cells. Blood (1995) 3.18
The EGF-CFC protein one-eyed pinhead is essential for nodal signaling. Cell (1999) 3.15
Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol (1998) 3.13
A beta-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation. J Biol Chem (1997) 3.12
Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med (1998) 3.05
Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev Biol (1997) 3.03
Applications of network BLAST server. Methods Enzymol (1996) 3.03
Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res (1999) 2.87
Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc Natl Acad Sci U S A (1999) 2.85
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol (1999) 2.78
Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer (2012) 2.74
Physicochemical foundations and structural design of hydrogels in medicine and biology. Annu Rev Biomed Eng (2000) 2.73
Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology (1999) 2.69
Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone (1999) 2.69
A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control (2003) 2.67
Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature (1998) 2.65
Association of an activator with an RNA polymerase II holoenzyme. Genes Dev (1995) 2.61
Mitochondrial genotype associated with longevity. Lancet (1998) 2.58
Hormonal changes in the grains of rice subjected to water stress during grain filling. Plant Physiol (2001) 2.52
Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest (2001) 2.49
Cellular mechanisms for developmental toxicity of chlorpyrifos: targeting the adenylyl cyclase signaling cascade. Toxicol Appl Pharmacol (1997) 2.42
Stoichiometric and steric principles governing repression by nuclear hormone receptors. Genes Dev (1997) 2.41
The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis (2003) 2.34
HIV knowledge and risk behaviour of female sex workers in Yunnan Province, China: potential as bridging groups to the general population. AIDS Care (2005) 2.34
Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J Biol Chem (1997) 2.33
Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery (2001) 2.30
A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data. Pharmacogenomics J (2010) 2.30
An assessment of the potential for reducing future combat deaths through medical technologies and training. J Trauma (2002) 2.29
Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology (1999) 2.27
Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J Virol (2004) 2.26
Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. Clin Chem (1999) 2.26
Poly (ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol Sci (1999) 2.25
Diffusion tensor imaging of the developing mouse brain. Magn Reson Med (2001) 2.20
Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med (2000) 2.20
Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res (1999) 2.19
Novel alternatives to antibiotics: bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides. J Appl Microbiol (2008) 2.19
The nitric oxide hypothesis of late preconditioning. Basic Res Cardiol (1998) 2.19
Premelting at defects within bulk colloidal crystals. Science (2005) 2.15
Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival. Immunity (2001) 2.11
The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene (2006) 2.09
Robust relational parsing over biomedical literature: extracting inhibit relations. Pac Symp Biocomput (2002) 2.09
Excessive activation of the alternative complement pathway in autosomal dominant polycystic kidney disease. J Intern Med (2014) 2.06
A class switch control region at the 3' end of the immunoglobulin heavy chain locus. Cell (1994) 2.04
Screening for prostatic carcinoma with prostate specific antigen. J Urol (1992) 2.03